Research & Development: Page 7
-
Permission granted by Sanofi
3 FDA approval dates to watch in the yearās final push
A handful of potential blockbusters are marching toward FDA review.
By Amy Baxter • Sept. 11, 2024 -
Permission granted by Organon
Why pharma should redefine āwomenās healthā
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
By Alexandra Pecci • Sept. 11, 2024 -
Explore the Trendlineā
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024 -
Getty Images via Getty Images
Huntingtonās disease R&D is regaining ground after several disappointments
Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.
By Kelly Bilodeau • Sept. 9, 2024 -
Scott Olson via Getty Images
Lilly lays down $1B to be āfirst in biologyā with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
By Amy Baxter • Sept. 9, 2024 -
Stock via Getty Images
What 3 layoff stories reveal about pharmaās troubles
The factors driving the industry’s layoffs — and what could help turn the tide.
By Meagan Parrish • Sept. 6, 2024 -
Permission granted by Pfizer
A plucky biotech threatening Pfizerās grip on the Prevnar vaccine market
Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.
By Michael Gibney • Sept. 4, 2024 -
Stock via Getty Images
Pharmaās āitā therapy ā a new drug class gaining steam
More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.
By Kelly Bilodeau • Sept. 4, 2024 -
Getty Images via Getty Images
Their Alzheimerās treatment worked ā but shares fell anyway
Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.
By Michael Gibney • Aug. 29, 2024 -
Stock via Getty Images
After an FDA rejection, hereās whatās next in the psychedelics pipeline
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
By Amy Baxter • Aug. 28, 2024 -
iStock via Getty Images
As pharmaās AI revolution gets underway, āhallucinationsā pose a great risk
While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.
By Michael Gibney • Aug. 27, 2024 -
Permission granted by Takeda Pharmaceuticals
Q&A // First 90 DaysWith a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
By Alexandra Pecci • Aug. 27, 2024 -
Mario Tama/ via Getty Images
As a new mpox strain gains ground, a key drug stumbles in the clinic
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
By Kelly Bilodeau • Aug. 26, 2024 -
Courtesy of 23andMe
Q&A23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
By Michael Gibney • Aug. 20, 2024 -
Stock via Getty Images
BMSā KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.
By Kelly Bilodeau • Aug. 19, 2024 -
Andreas Rentz via Getty Images
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
The German biotech is leveraging its mRNA platforms to develop a new class of cancer treatments that are necessary to lift the company’s flagging sales.
By Amy Baxter • Aug. 14, 2024 -
Getty Images via Getty Images
Q&A // Biotech SpotlightA biotechās difficult journey to bring a new kind of Parkinsonās drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
By Michael Gibney • Aug. 13, 2024 -
Permission granted by Immunic Therapeutics
A potential MS āgame changerā could bring more safety to the table ā even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
By Alexandra Pecci • Aug. 13, 2024 -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024 -
Courtesy of Roche
Roche licenses Sangamoās technology for another shot at Alzheimerās drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
By Jacob Bell • Aug. 8, 2024 -
Stock via Getty Images
Q&AAutobahnās road to a breakthrough depression treatment is paved with high-profile investors
The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.
By Amy Baxter • Aug. 7, 2024 -
Permission granted by Arialys Therapeutics
Biotech SpotlightA biotech dousing āfiresā in the brain that plagued a bestselling author
Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.
By Alexandra Pecci • Aug. 7, 2024 -
Permission granted by University of Pennsylvania
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.
By Ned Pagliarulo • Aug. 5, 2024 -
Stock via Getty Images
In a Duchenne market beset by problems, Capricor data marks a bright spot
The company’s cell therapy recently showed positive results from a mid-stage trial.
By Kelly Bilodeau • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024
Previous
